Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vitamin D3 + Calcium is a combination nutritional supplement developed and marketed by Saimirra Innopharm for the management of calcium and vitamin D deficiencies and the prevention of osteoporosis. The product typically consists of cholecalciferol (Vitamin D3) and a calcium salt, most commonly calcium carbonate. Calcium is a critical mineral for maintaining bone density and structural integrity, while Vitamin D3 acts as a pro-hormone that is converted to its active form, calcitriol, which binds to the Vitamin D receptor (VDR) to enhance intestinal calcium absorption and maintain serum calcium homeostasis. This combination is widely used to support bone health, particularly in populations at risk for bone loss or inadequate dietary intake.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cholecalciferol + calcium.